Literature DB >> 28892185

Prevalence, comorbidities and mortality of toxic shock syndrome in children and adults in the USA.

Mark A Strom1, Derek Y Hsu1, Jonathan I Silverberg2.   

Abstract

Toxic Shock Syndrome (TSS), a superantigen-mediated illness, is characterized by rash, hypotension and multi-organ dysfunction. Predictors of TSS and related morbidity and mortality are poorly defined. In this study, data on 61,959,084 hospitalizations from the 2003-2012 Nationwide Inpatient Sample, a 20% stratified sample of US hospitalizations, were analyzed and ICD-9-CM coding used to identify 4491 hospitalizations with a diagnosis of TSS. Incidence, in-hospital mortality rate, comorbidities, length of stay and costs of care attributable to TSS were determined. In multivariate survey logistic regression models, TSS was associated with female sex (adjusted odds ratio [95% confidence interval], 1.54 [1.48-1.60]), younger age (0-17 years, 2.17 [2.06-2.29]; 40-59: 0.53 [0.50-0.56]; 60-79: 0.28 [0.26-0.30]; 80+: 0.13 [0.11-0.14] compared with 18-39) and race/ethnicity (black, 0.63 [0.59-0.67]; Hispanic: 0.60 [0.56-0.64]; Asian, 1.11 [1.00-1.11]; and other, 0.83 [0.75-0.92] compared with white). Patients with TSS had a three-fold greater cost of care (mean: $36,656 ± 942) and length of stay (LOS) (mean: 10.65 ± 0.23 days) than patients without TSS. Shared predictors of increased LOS and costs in patients with TSS were male sex; age 40-79 years; Black, Hispanic, Asian and other race/ethnicity; and more than one chronic condition. Predictors of in-hospital mortality included respiratory failure (13.66 [11.37-16.43]), liver disease/failure (3.36 [2.59-4.34]), chickenpox (91.26 [27.74-300.25]), coagulopathy (2.14 [1.85-2.48]), and higher age. In conclusion, there are significant racial/ethnic, socioeconomic, and comorbid disparities in the incidence and mortality of TSS in adults and children in the USA.
© 2017 The Societies and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  comorbidity; epidemiology; healthcare burden; toxic shock syndrome

Mesh:

Year:  2017        PMID: 28892185     DOI: 10.1111/1348-0421.12539

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  5 in total

1.  Clinical Profile, Intensive Care Needs, and Short-Term Outcome of Toxic Shock Syndrome Among Children: A 10-Year Single-Centre Experience from North India.

Authors:  Suresh Kumar Angurana; Puspraj Awasthi; Sudeep K C; Karthi Nallasamy; Arun Bansal; Muralidharan Jayashree
Journal:  Indian J Pediatr       Date:  2022-07-08       Impact factor: 5.319

2.  Staphylococcal toxic shock syndrome in a lactating mother with breast abscess: A case report.

Authors:  Kamal Pandit; Sushil Khanal; Prabhat Adhikari; Samaj Adhikari; Subhash Prasad Acharya
Journal:  Ann Med Surg (Lond)       Date:  2020-07-22

Review 3.  Device-Associated Menstrual Toxic Shock Syndrome.

Authors:  Patrick M Schlievert; Catherine C Davis
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

4.  Toxic Shock Syndrome in Patients Younger than 21 Years of Age, United States, 2006-2018.

Authors:  Jessica Leung; Joseph Y Abrams; Ryan A Maddox; Shana Godfred-Cato; Lawrence B Schonberger; Ermias D Belay
Journal:  Pediatr Infect Dis J       Date:  2021-03-01       Impact factor: 3.806

5.  Association of characteristics of tampon use with menstrual toxic shock syndrome in France.

Authors:  Amaury Billon; Marie-Paule Gustin; Anne Tristan; Thomas Bénet; Julien Berthiller; Claude Alexandre Gustave; Philippe Vanhems; Gerard Lina
Journal:  EClinicalMedicine       Date:  2020-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.